Cargando…
Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been widely used in the treatment of locally advanced non-small cell lung cancer (NSCLC). The phenomenon of pseudoprogression in targeted therapy in EGFR-mutation NSCLC patients is rare. Here, we reported an EGFR-mutation-p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468776/ https://www.ncbi.nlm.nih.gov/pubmed/36110968 http://dx.doi.org/10.3389/fonc.2022.971192 |
_version_ | 1784788492055740416 |
---|---|
author | Ren, Fei Wang, Yao Gao, Yongsheng Meng, Xiangjiao |
author_facet | Ren, Fei Wang, Yao Gao, Yongsheng Meng, Xiangjiao |
author_sort | Ren, Fei |
collection | PubMed |
description | Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been widely used in the treatment of locally advanced non-small cell lung cancer (NSCLC). The phenomenon of pseudoprogression in targeted therapy in EGFR-mutation NSCLC patients is rare. Here, we reported an EGFR-mutation-positive lung adenocarcinoma patient who was admitted to a hospital for cough and chest distress accompanied by shortness of breath. He underwent four cycles of chemotherapy with pemetrexed combined with carboplatin and concurrent radiotherapy in the third and fourth cycles. Then, he was treated by osimertinib maintenance therapy. After 11.5 months of osimertinib treatment, he was assessed to progressive disease by computed tomography. He underwent fiber bronchoscopy, and the biopsy pathology showed extensive necrosis without tumor cells. Until now, the patient has continued on osimertinib for 7 months without relapse or metastasis. As far as we know, we are the first to report pseudoprogression in osimertinib maintenance after definitive chemoradiation. This study reminds the clinicians to distinguish pseudoprogression from osimertinib-induced progression and avoid abandoning effective treatments. |
format | Online Article Text |
id | pubmed-9468776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94687762022-09-14 Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report Ren, Fei Wang, Yao Gao, Yongsheng Meng, Xiangjiao Front Oncol Oncology Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been widely used in the treatment of locally advanced non-small cell lung cancer (NSCLC). The phenomenon of pseudoprogression in targeted therapy in EGFR-mutation NSCLC patients is rare. Here, we reported an EGFR-mutation-positive lung adenocarcinoma patient who was admitted to a hospital for cough and chest distress accompanied by shortness of breath. He underwent four cycles of chemotherapy with pemetrexed combined with carboplatin and concurrent radiotherapy in the third and fourth cycles. Then, he was treated by osimertinib maintenance therapy. After 11.5 months of osimertinib treatment, he was assessed to progressive disease by computed tomography. He underwent fiber bronchoscopy, and the biopsy pathology showed extensive necrosis without tumor cells. Until now, the patient has continued on osimertinib for 7 months without relapse or metastasis. As far as we know, we are the first to report pseudoprogression in osimertinib maintenance after definitive chemoradiation. This study reminds the clinicians to distinguish pseudoprogression from osimertinib-induced progression and avoid abandoning effective treatments. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9468776/ /pubmed/36110968 http://dx.doi.org/10.3389/fonc.2022.971192 Text en Copyright © 2022 Ren, Wang, Gao and Meng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ren, Fei Wang, Yao Gao, Yongsheng Meng, Xiangjiao Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report |
title | Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report |
title_full | Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report |
title_fullStr | Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report |
title_full_unstemmed | Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report |
title_short | Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report |
title_sort | pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage iii non-small cell lung cancer: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468776/ https://www.ncbi.nlm.nih.gov/pubmed/36110968 http://dx.doi.org/10.3389/fonc.2022.971192 |
work_keys_str_mv | AT renfei pseudoprogressionwithosimertinibafterdefinitivechemoradiationinunresectableepidermalgrowthfactorreceptormutationpositiveofstageiiinonsmallcelllungcanceracasereport AT wangyao pseudoprogressionwithosimertinibafterdefinitivechemoradiationinunresectableepidermalgrowthfactorreceptormutationpositiveofstageiiinonsmallcelllungcanceracasereport AT gaoyongsheng pseudoprogressionwithosimertinibafterdefinitivechemoradiationinunresectableepidermalgrowthfactorreceptormutationpositiveofstageiiinonsmallcelllungcanceracasereport AT mengxiangjiao pseudoprogressionwithosimertinibafterdefinitivechemoradiationinunresectableepidermalgrowthfactorreceptormutationpositiveofstageiiinonsmallcelllungcanceracasereport |